An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization
Background: Endometrial cancer (EC) is the most common gynecologic tumor and the world’s fourth most common cancer in women. Most patients respond to first-line treatments and have a low risk of recurrence, but refractory patients, and those with metastatic cancer at diagnosis, remain with no treatm...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/5/794 |
| _version_ | 1827752869533581312 |
|---|---|
| author | Federica Torricelli Elisabetta Sauta Veronica Manicardi Vincenzo Dario Mandato Andrea Palicelli Alessia Ciarrocchi Gloria Manzotti |
| author_facet | Federica Torricelli Elisabetta Sauta Veronica Manicardi Vincenzo Dario Mandato Andrea Palicelli Alessia Ciarrocchi Gloria Manzotti |
| author_sort | Federica Torricelli |
| collection | DOAJ |
| description | Background: Endometrial cancer (EC) is the most common gynecologic tumor and the world’s fourth most common cancer in women. Most patients respond to first-line treatments and have a low risk of recurrence, but refractory patients, and those with metastatic cancer at diagnosis, remain with no treatment options. Drug repurposing aims to discover new clinical indications for existing drugs with known safety profiles. It provides ready-to-use new therapeutic options for highly aggressive tumors for which standard protocols are ineffective, such as high-risk EC. Methods: Here, we aimed at defining new therapeutic opportunities for high-risk EC using an innovative and integrated computational drug repurposing approach. Results: We compared gene-expression profiles, from publicly available databases, of metastatic and non-metastatic EC patients being metastatization the most severe feature of EC aggressiveness. A comprehensive analysis of transcriptomic data through a two-arm approach was applied to obtain a robust prediction of drug candidates. Conclusions: Some of the identified therapeutic agents are already successfully used in clinical practice to treat other types of tumors. This highlights the potential to repurpose them for EC and, therefore, the reliability of the proposed approach. |
| first_indexed | 2024-03-11T07:29:07Z |
| format | Article |
| id | doaj.art-c0fe1a47c2524934a108fc5e7287df97 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T07:29:07Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-c0fe1a47c2524934a108fc5e7287df972023-11-17T07:28:13ZengMDPI AGCells2073-44092023-03-0112579410.3390/cells12050794An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer MetastatizationFederica Torricelli0Elisabetta Sauta1Veronica Manicardi2Vincenzo Dario Mandato3Andrea Palicelli4Alessia Ciarrocchi5Gloria Manzotti6Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, ItalyLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, ItalyLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, ItalyUnit of Obstetrics and Gynaecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyPathology Unit, Department of Oncology and Advanced Technologies, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, ItalyLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, ItalyBackground: Endometrial cancer (EC) is the most common gynecologic tumor and the world’s fourth most common cancer in women. Most patients respond to first-line treatments and have a low risk of recurrence, but refractory patients, and those with metastatic cancer at diagnosis, remain with no treatment options. Drug repurposing aims to discover new clinical indications for existing drugs with known safety profiles. It provides ready-to-use new therapeutic options for highly aggressive tumors for which standard protocols are ineffective, such as high-risk EC. Methods: Here, we aimed at defining new therapeutic opportunities for high-risk EC using an innovative and integrated computational drug repurposing approach. Results: We compared gene-expression profiles, from publicly available databases, of metastatic and non-metastatic EC patients being metastatization the most severe feature of EC aggressiveness. A comprehensive analysis of transcriptomic data through a two-arm approach was applied to obtain a robust prediction of drug candidates. Conclusions: Some of the identified therapeutic agents are already successfully used in clinical practice to treat other types of tumors. This highlights the potential to repurpose them for EC and, therefore, the reliability of the proposed approach.https://www.mdpi.com/2073-4409/12/5/794drug repurposingendometrial cancergene expressionmetastasisPI3K pathway |
| spellingShingle | Federica Torricelli Elisabetta Sauta Veronica Manicardi Vincenzo Dario Mandato Andrea Palicelli Alessia Ciarrocchi Gloria Manzotti An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization Cells drug repurposing endometrial cancer gene expression metastasis PI3K pathway |
| title | An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization |
| title_full | An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization |
| title_fullStr | An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization |
| title_full_unstemmed | An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization |
| title_short | An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization |
| title_sort | innovative drug repurposing approach to restrain endometrial cancer metastatization |
| topic | drug repurposing endometrial cancer gene expression metastasis PI3K pathway |
| url | https://www.mdpi.com/2073-4409/12/5/794 |
| work_keys_str_mv | AT federicatorricelli aninnovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT elisabettasauta aninnovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT veronicamanicardi aninnovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT vincenzodariomandato aninnovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT andreapalicelli aninnovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT alessiaciarrocchi aninnovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT gloriamanzotti aninnovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT federicatorricelli innovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT elisabettasauta innovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT veronicamanicardi innovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT vincenzodariomandato innovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT andreapalicelli innovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT alessiaciarrocchi innovativedrugrepurposingapproachtorestrainendometrialcancermetastatization AT gloriamanzotti innovativedrugrepurposingapproachtorestrainendometrialcancermetastatization |